Capricor (CAPR) Q2 2026 Earnings Call Transcript

Capricor Therapeutics reported Q2 2026 results with a net loss of $40.7 million ($0.70 per share) and cash reserves of $237.9 million. The company faced a significant setback when the FDA Advisory Committee voted 3-9 against approving Deramiocel for cardiomyopathy in DMD patients. However, management plans to submit a BLA amendment focusing on upper limb skeletal muscle function, supported by positive HOPE-3 primary endpoint data showing statistically significant slowing of disease progression (p=0.029). The company is scaling manufacturing capacity and pursuing arbitration with NS Pharma over distribution agreement disputes.